What Ambrose Healthcare does

Ambrose Healthcare Ltd is a private UK pharmaceutical company incorporated in October 2022 and launched in early 2023, headquartered in Wrexham (Welsh operations) and registered in Cambridge, England. The company acquires and develops late-stage drug candidates that already have human safety and efficacy data, targeting rare disease indications where no approved treatment exists — approximately 95% of the ~7,000 known rare diseases affecting roughly 400 million people globally. Its current pipeline comprises two clinical-stage assets: renzapride, a dual 5HT4 agonist/5HT3 antagonist prokinetic agent with prior data from over 3,000 patients being developed for gastrointestinal symptoms in cystic fibrosis (Phase 2 ready); and VAL401, a reformulated risperidone in a lipid-based capsule inhibiting the HSD10 enzyme, being developed for quality of life and cachexia in stage 3-4 pancreatic cancer and other oncology indications (Phase 2). Global rights to renzapride were acquired in October 2024 and to VAL401 in June 2025 via a ValiSeek/ValiRx licensing agreement carrying up to £16 million in milestones plus royalties.

The company's model is asset-flip biotech in structure: in-license de-risked clinical assets, execute focused development under Orphan Drug Designation pathways, then commercialize either directly via hospital and specialist pharmacy distribution or through outbound territory licensing. Ambrose does not have products on market and is pre-revenue; pricing is determined post-approval or under Named Patient Supply frameworks on a country-by-country basis. Its go-to-market leverages an international network that includes the US Cystic Fibrosis Foundation, Aparito (digital eCOA endpoints), BioPhy (AI-powered clinical trial outcome prediction at reported 80% accuracy), ValiSeek/ValiRx, Welsh ecosystem partners (MediWales, Life Sciences Hub Wales, Innovate UK), and Middle East partners (SEHA, IROS) accessed via the Arab Health conference.

The leadership team has 200+ years of combined pharmaceutical experience, with prior track record of raising £200 million and delivering £1 billion of shareholder value across ventures including Atlantic Healthcare. Recent C-suite additions include ex-GSK IP leadership, ex-AstraZeneca operations, and ex-PwC Cambridge biotech finance — brought in to ready the company for pivotal clinical execution and a larger capital raise. Ambrose won the MediWales National Life Sciences Start-Up of the Year 2023 and OBN Best Startup Biotech Company 2024.

Name

Ambrose Healthcare

Legal name

Ambrose Healthcare Ltd

Website

https://ambrosehc.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Ambrose Healthcare is a private UK pharmaceutical company that acquires and develops late-stage drug candidates for rare diseases with no approved treatment. Its pipeline includes renzapride for cystic fibrosis GI symptoms and VAL401 for oncology, targeting orphan drug pathways.

Ownership category

akta.pro rank

Product category

Rare Disease Pharmaceuticals

SIC

Services-Health Services (8000)

akta.pro primary industry

Rare Renal & Nephrology Disorder Therapies (HLAIAIAI)

akta.pro secondary industry

Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC)

Keywords

• Rare disease therapeutics
• Late-stage drug development
• Orphan drug designation
• Specialty pharmaceuticals
• Clinical-stage biotech

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Drug Development and Commercialization: Ambrose Healthcare acquires, develops, and commercializes late-stage drug candidates for rare disease indications. Revenue will be generated through the approval and sale of therapeutic products, leveraging rare disease regulatory pathways (Orphan Drug Designation) and market exclusivity provisions. The company also considers Named Patient Supply for early-access programs.
2. Milestone and Royalty Payments (inbound licensing): Under licensing agreements such as VAL401 from ValiSeek, Ambrose receives global development and commercialization rights in exchange for clinical and commercial milestone payments and royalties. Milestone payments to ValiSeek total up to £16 million plus royalties upon achievement of development and regulatory milestones.
3. Outbound Licensing and Distribution: Once assets are approved, Ambrose commercializes drug products, generating revenue through product sales and potentially licensing to other pharmaceutical companies in specific territories.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels8 records

Core offering

Ambrose Healthcare is an entrepreneurial pharmaceutical company that acquires, develops, and commercializes late-stage drug candidates for rare disease indications with no approved treatment. Its current pipeline includes Renzapride for gastrointestinal symptoms in cystic fibrosis and VAL401 for oncology palliative care applications. The company leverages rare disease regulatory pathways such as Orphan Drug Designation to accelerate approvals and bring treatments to market faster and at lower cost.

Product overview

Ambrose Healthcare is an entrepreneurial pharmaceutical company developing a late-stage drug portfolio for rare diseases. The company's pipeline consists of two clinical-stage therapeutic candidates: Renzapride, a prokinetic agent for gastrointestinal symptoms in cystic fibrosis (Phase 2 ready), and VAL401, a reformulated risperidone for oncology applications including pancreatic cancer (Phase 2). The company acquires and develops drug candidates with existing human safety and efficacy data, leveraging rare disease regulatory pathways to accelerate approvals.

Differentiator

Problem solved

Functional benefit

Products and services

• Renzapride Renzapride is an investigational prokinetic agent with dual mode of action (5HT4 agonist and 5HT3 antagonist) being developed for gastrointestinal symptoms in cystic fibrosis patients, with demonstrated efficacy and safety in clinical studies involving over 3,000 patients.
• VAL401 VAL401 is a reformulation of risperidone in a lipid-based oral capsule targeting cancer cell metabolism via HSD10 enzyme inhibition, being developed for quality of life palliative care and cachexia in Stage 3-4 pancreatic cancer patients.

Quantifiable outcome

• Target of bringing drug therapies to market in half the time compared to current industry standards, and at a lower cost
• +4 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

16 partnerships are on record, tiered core and minor.

• ValiSeek Limited (subsidiary of ValiRx plc)coreStrategic or Co-development Partner · 5 December 2023ValiSeek granted Ambrose an exclusive option to license VAL401, a novel oncology therapeutic (repurposed risperidone formulation), with clinical and commercial milestone payments up to £16 million plus royalties. In June 2025, Ambrose exercised the option for full global rights to VAL401 for oncology and rare disease applications. ValiRx received 576,000 ordinary shares in Ambrose.
• AparitocoreStrategic or Co-development Partner · 27 July 2023Aparito, a rare disease clinical trial specialist and part of the Welsh healthcare ecosystem, joined Ambrose Healthcare's collaborative network to tackle unmet needs in rare disease drug development. Aparito's Atom5™ platform provides digital biomarkers, smartphone apps, video assessments, and wearable technology to generate novel eCOA endpoints for clinical trials, addressing the challenge of quantifying patient outcomes in rare disease studies.
• US Cystic Fibrosis FoundationcoreStrategic or Co-development PartnerThe US Cystic Fibrosis Foundation provided expert input into the Phase 2 study protocol for renzapride in gastrointestinal symptoms of cystic fibrosis. This collaboration is part of Ambrose's network of rare disease experts and stakeholders.
• BioPhycoreTechnology or IntegrationAmbrose partnered with BioPhy, which provides AI-powered clinical development tools. BioPhy has a reported 80% accuracy rate for predicting clinical trial successes, which Ambrose leverages to identify and select the most promising drug assets for development.
• CamRareminorStrategic or Co-development PartnerPart of Ambrose's international network of rare disease organizations. CamRare is a UK-based rare disease organization supporting collaboration in the rare disease ecosystem.
• OBN (Oxford Biotech Network)minorStrategic or Co-development PartnerOBN is the UK's most innovative life sciences membership network focused on catalyzing growth and success. Ambrose is an OBN member and was recognized through OBN Awards 2024.
• MediWalesminorStrategic or Co-development PartnerMediWales is a life sciences industry network in Wales. Ambrose won the National Life Sciences Start-Up of the Year Award 2023 at the MediWales Innovation Awards and participates in MediWales events and publications.
• Innovate UKminorStrategic or Co-development PartnerInnovate UK is the UK's national innovation agency. Part of Ambrose's international network of rare disease organizations and collaborators.
• Life Sciences Hub Wales / Wales Lifecycle HubminorStrategic or Co-development PartnerLife Sciences Hub Wales and Wales Lifecycle Hub are part of the Welsh healthcare ecosystem supporting Ambrose's operations and collaborations in Wales.
• Smartway PharmaceuticalsminorStrategic or Co-development PartnerSmartway Pharmaceuticals is part of Ambrose's international network of rare disease collaborators, providing expertise in pharmaceutical development.
• Atlantic HealthcareminorStrategic or Co-development PartnerAtlantic Healthcare is listed as part of Ambrose's international network of rare disease organizations.
• UK Discovery HealthminorStrategic or Co-development PartnerUK Discovery Health is part of Ambrose's international network of rare disease organizations.
• LSPA (Life Sciences Partnership Accelerator)minorStrategic or Co-development PartnerLSPA member listed as part of Ambrose's network of rare disease collaborators.
• BoydsminorStrategic or Co-development PartnerBoyds is listed as a partner in Ambrose's network, providing pharmaceutical and biotech expertise.
• SEHA (Abu Dhabi Health Services Company)minorStrategic or Co-development PartnerSEHA is part of Ambrose's international network supporting rare disease collaborations and healthcare ecosystem connections in the Middle East.
• IROS (UAE's first homegrown CRO)minorStrategic or Co-development PartnerIROS is the UAE's first homegrown contract research organization, supporting clinical trials in healthcare research. Ambrose meets with IROS at Arab Health as part of building its Middle East healthcare network.

Scale indicators10 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Alizyme Therapeutics plc: Former developer of renzapride for IBS-C indications, with renzapride now reacquired by Ambrose. Operates in the same small-molecule, late-stage rare-disease/GI specialty. Direct historical comparator for the same molecule Ambrose is re-purposing.
• ValiRx plc: UK-listed clinical-stage oncology and rare-disease company whose subsidiary ValiSeek is the licensor of VAL401 to Ambrose. Operates in the same orphan-drug development niche and shares direct commercial alignment through the licensing deal.
• Octavian Therapeutics: Biotech previously led through a £16.5m LSE IPO by CSO Clarissa Sowemimo-Coker. Closely aligned execution playbook and stage profile (UK clinical-stage rare-disease / specialty pharma), making it a strong comparable for Ambrose's capital-markets trajectory.
• Laverock Therapeutics: UK early-stage biotech where CFO Ali Elsley led the >£20m seed raise. Directly comparable UK biotech at similar stage and capital structure, with overlapping leadership background and rare-disease / gene-therapy adjacency.
• Atlantic Healthcare: Pharmaceutical company previously founded by Toby Wilson Waterworth (Ambrose's Founder & Chairman), which delivered 30x returns to early investors. Same executive playbook (acquire de-risked rare-disease assets) and overlaps directly with renzapride's developer.

Broad incumbents

• Vertex Pharmaceuticals: Dominant commercial player in cystic fibrosis (Kalydeco, Trikafta) and a major rare-disease franchise. Direct therapeutic-area overlap with Ambrose's lead CF GI indication and the most relevant incumbent benchmark for CF market access and pipeline strategy.
• BioMarin Pharmaceutical: Pure-play rare-disease biopharmaceutical company with a globally commercialized orphan drug portfolio (e.g., Vimizim, Naglazyme). Closest broad incumbent to Ambrose's specialized rare-disease business model.
• Ultragenyx Pharmaceutical: Clinical and commercial rare-disease company built on in-licensing/acquiring late-stage orphan assets with existing clinical data - structurally analogous to Ambrose's asset-acquisition model. Comparable business model and stage-mix.

Emerging players

• BioPhy: AI-powered clinical-trial-outcome prediction platform that is Ambrose's core technology partner (reported 80% trial-success accuracy). Emerging player applying AI to pharma asset selection; comparable as an enabling layer for the rare-disease pipeline strategy.
• Bicycle Therapeutics: UK clinical-stage biotech with overlapping leadership - Sally Curran was previously Head of IP at Bicycle before joining Ambrose. Comparable UK-listed clinical-stage platform company pursuing high-value orphan/rare-disease and oncology indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/89288356/admin/dashboard
• Xx.com/ambrosehlthcare

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ambrose Healthcare